Paasheuvelweg 25a
Amsterdam 1105 BP
Netherlands
31 20 240 6000
http://www.uniqure.com
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 212
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Matthew Craig Kapusta | CEO, Interim CFO & Exec. Director | 883.62k | N/A | 1972 |
| Dr. Scott T. McMillan | Chief Operations Officer | 595.6k | N/A | 1959 |
| Ms. Maria E. Cantor | Sr. VP of Investor Relations & Communication | 491.12k | N/A | 1968 |
| Mr. Jonathan Garen | Chief Bus. Officer | 560.13k | N/A | 1966 |
| Dr. Alexander E. Kuta Ph.D. | Sr. VP of Regulatory Affairs | 594.99k | N/A | 1960 |
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure. In addition, the company engages in developing AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment hemophilia A; AMT-190, a differentiated gene therapy for the treatment of Fabry disease; and AMT-150, a gene therapy for SCA3, a central nervous system disorder. The company has collaboration and license agreements with Bristol Myers-Squibb; 4D Molecular Therapeutics, LLC; and Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
uniQure N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.